[Corrections] Correction to Lancet Oncol 2024; 25: e139–51

Browne IM, André F, Chandarlapaty S, Carey LA, Turner NC. Optimal targeting of PI3K-AKT and mTOR in advanced oestrogen receptor-positive breast cancer. Lancet Oncology 2024; 25: e139–51—In this Review, a drug name in the first column of table 1 should have read “STX-478”. This correction has been made to the online version as of May 28, 2024.